论文部分内容阅读
中枢神经系统存在血脑屏障且缺乏淋巴组织和树突细胞,加之肿瘤周围建立的免疫抑制微环境,都使神经系统恶性胶质瘤的免疫治疗面临许多特殊的困难。以树突细胞为基础的免疫治疗是指树突细胞肿瘤疫苗的接种治疗,它可以部分或全部改善胶质瘤患者神经系统的免疫状况,因此可以成为有效的治疗方法。随着分子生物学和基因工程技术的发展,树突细胞肿瘤疫苗的制备、优化和应用技术得到了很大提高,为其未来临床应用奠定了良好的基础。
The presence of the blood-brain barrier in the central nervous system and the absence of lymphoid tissue and dendritic cells, coupled with the immunosuppressive microenvironment established around the tumor, render the immunotherapy of the malignant system of the nervous system several particular difficulties. Dendritic cell-based immunotherapy refers to the vaccination of dendritic cell tumor vaccines, which can partially or completely improve the immune status of the nervous system in glioma patients and can therefore be an effective treatment. With the development of molecular biology and genetic engineering technology, the preparation, optimization and application of dendritic cell tumor vaccine have been greatly improved, which has laid a good foundation for its future clinical application.